Alliance Pharmaceutical Corp. and Hoechst Marion Roussel Inc. announced late Friday that they have terminated their agreement to develop ALLP's LiquiVent perflubron liquid to treat acute respiratory distress syndrome (ARDS).

The move marks at least the fifth biotech collaboration HMR has dropped since the beginning of 1996, when a reevaluation of projects occurred following the merger of Hoechst AG with Marion Merrill Dow. Dropped partnerships include ImmuLogic Pharmaceutical Corp., Scios Inc., Alteon Inc. and Cortech Inc. In addition, a deal with Proscript was restructed.